The European Medicines Agency (EMA) has accepted for review Bristol-Myers Squibb’s (NYSE:BMY) marketing application seeking approval of lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B) after at least two prior therapies.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.